|Mr. Christopher Peetz||Pres, CEO & Director||785.22k||N/A||1979|
|Dr. Ian Clements||Chief Financial Officer||541.15k||N/A||1969|
|Mr. Peter Radovich M.B.A., Ph.D.||Chief Operating Officer||524.85k||N/A||1978|
|Dr. Pamela Vig Ph.D.||Chief Scientific Officer||N/A||N/A||1971|
|Mr. Paul K. Ross||Chief Compliance Officer||N/A||N/A||N/A|
|Ms. Lara Longpre MSC, MBA||Chief Devel. Officer||N/A||N/A||1970|
|Dr. Edwin Jonathan Tucker M.D.||Chief Medical Officer||N/A||N/A||1972|
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Mirum Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.